-
1
Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
Published 2024-11-01Subjects: Get full text
Article -
2
Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
Published 2025-01-01Subjects: “…Sodium–glucose cotransporter-2 inhibitors…”
Get full text
Article -
3
Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
Published 2023-11-01Subjects: “…sodium-glucose cotransporter-2 inhibitor…”
Get full text
Article -
4
Impact of dapagliflozin on metabolic phenotype, hormone levels, and fertility in female mice after prolonged high-fat diet
Published 2025-01-01Subjects: “…sodium-glucose cotransporter 2…”
Get full text
Article -
5
Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report
Published 2025-01-01Subjects: Get full text
Article -
6
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
Published 2022-06-01Subjects: Get full text
Article -
7
-
8
The road ahead: emerging therapies for primary IgA nephropathy
Published 2025-02-01Subjects: Get full text
Article -
9
The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
Published 2022-06-01Subjects: “…Adult congenital heart diseaseChronic heart failureSodium‐glucose cotransporter inhibitor…”
Get full text
Article -
10
Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized cont...
Published 2025-01-01Subjects: “…sodium-glucose-cotransporter-2 (SGLT2) inhibitors…”
Get full text
Article -
11
-
12